Androgen Deprivation Therapy (ADT) Market Regional Analysis
Approval for new drugs is expected to boost the global androgen deprivation therapy (ADT) market growth over the forecast period. For instance, in November 2017, European Commission (EC) granted approval to Janssen-Cilag International NV (Janssen) for broadening the existing marketing authorization for its drug Zytiga (abiraterone acetate). The approval enables the company to include the drug in treatment of metastatic prostate cancer’s early stages along with ADT. Such new drug approvals are expected to propel Europe androgen deprivation therapy (ADT) market growth over the forecast period.
By Region
Androgen Deprivation Therapy (ADT) Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients